Topical Atropine for Myopia Control: A Review

Abstract

Over the past decade, atropine has emerged as an effective intervention for preventing myopia in children. Multiple randomized controlled trials, mainly from Asia, have demonstrated the safety and efficacy of topical atropine for myopia control. Both efficacy and side effects exhibit a positive dose-response relationship. This review focuses on new data from studies with predominantly white populations, ethnicity-dependent differences in efficacy and side effects, and primary prevention of incident myopia with atropine.

Zusammenfassung

In der letzten Dekade hat sich Atropin als wirksames Mittel zur Prävention von Myopie bei Kindern erwiesen. Mehrere randomisierte kontrollierte Studien, vor allem aus Asien, konnten die Sicherheit und Wirksamkeit von topischem Atropin bestätigen. Sowohl die Wirksamkeit als auch die Nebenwirkungen weisen eine positive Dosis-Wirkungs-Beziehung auf. Diese Übersichtsarbeit konzentriert sich auf neue Daten aus Studien mit überwiegend weißen Bevölkerungsgruppen, auf ethnisch bedingte Unterschiede in der Wirksamkeit und den Nebenwirkungen sowie auf die Primärprävention (Verhindern der Erstmanifestation) von Myopie mit Atropin.

Keywords

pediatric ophthalmology - myopia - myopia prevention - myopia control - myopia management - atropine

Schlüsselwörter

Kinderophthamologie - Myopie - Atropin - Myopieprävention

Publication History

Received: 05 April 2024

Accepted: 11 April 2024

Article published online:
27 May 2024

• References

• 1 Tideman JWL, Snabel MCC, Tedja MS. et al. Association of Axial Length With Risk of Uncorrectable Visual Impairment for Europeans With Myopia. JAMA Ophthalmol 2016; 134: 1355-1363
• 2 Bullimore MA, Ritchey ER, Shah S. et al. The Risks and Benefits of Myopia Control. Ophthalmology 2021; 128: 1561-1579
• 3 Jonas JB, Ang M, Cho P. et al. IMI prevention of myopia and its progression. Invest Ophthalmol Vis Sci 2021; 62: 6
• 4 Lawrenson JG, Shah R, Huntjens B. et al. Interventions for myopia control in children: a living systematic review and network meta-analysis. Cochrane Database Syst Rev 2023; (02) CD014758
• 5 Derby H. On the Atropine Treatment of Acquired and Progressive Myopia. Trans Am Ophthalmol Soc 1874; 2: 139-154
• 6 Schröder C. Ueber Atropinkuren gegen Kurzsichtigkeit. Zeitschrift für Augenheilkunde 1874.
• 7 Chia A, Chua WH, Cheung YB. et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5 %, 0.1 %, and 0.01 % doses (Atropine for the Treatment of Myopia 2). Ophthalmology 2012; 119: 347-354
• 8 Chua WH, Balakrishnan V, Chan YH. et al. Atropine for the treatment of childhood myopia. Ophthalmology 2006; 113: 2285-2291
• 9 Yam JC, Zhang XJ, Zhang Y. et al. Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout: Phase 3 Report. Ophthalmology 2022; 129: 308-321
• 10 Brennan NA, Toubouti YM, Cheng X. et al. Efficacy in myopia control. Prog Retin Eye Res 2021; 83: 100923
• 11 Ha A, Kim SJ, Shim SR. et al. Efficacy and Safety of 8 Atropine Concentrations for Myopia Control in Children: A Network Meta-Analysis. Ophthalmology 2022; 129: 322-333
• 12 Lee SS, Lingham G, Blaszkowska M. et al. Low‐concentration atropine eyedrops for myopia control in a multi‐racial cohort of Australian children: A randomised clinical trial. Clin Experiment Ophthalmol 2022; 50: 1001-1012
• 13 Loughman J, Kobia-Acquah E, Lingham G. et al. Myopia outcome study of atropine in children: Two-year result of daily 0.01 % atropine in a European population. Acta Ophthalmol 2024; 102: e245-e256
• 14 Zadnik K, Schulman E, Flitcroft I. et al. Efficacy and Safety of 0.01 % and 0.02 % Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial. JAMA Ophthalmol 2023; 141: 990-999
• 15 Repka MX, Weise KK, Chandler DL. et al. Low-Dose 0.01 % Atropine Eye Drops vs. Placebo for Myopia Control. JAMA Ophthalmol 2023; 141: 756-765
• 16 Richdale K, Tomiyama ES, Novack GD. et al. Compounding of Low-Concentration Atropine for Myopia Control. Eye Contact Lens 2022; 48: 489-492
• 17 Hansen NC, Hvid-Hansen A, Møller F. et al. Two-Year Results of 0.01 % Atropine Eye Drops and 0.1 % Loading Dose for Myopia Progression Reduction in Danish Children: A Placebo-Controlled, Randomized Clinical Trial. J Pers Med 2024; 14: 175
• 18 Farassat N, Böhringer D, Küchlin S. et al. Low-dose AtropIne for Myopia Control in Children (AIM): protocol for a randomised, controlled, double-blind, multicentre, clinical trial with two parallel arms. BMJ Open 2023; 13: e068822
• 19 Li Y, Yip M, Ning Y. et al. Topical Atropine for Childhood Myopia Control: The Atropine Treatment Long-Term Assessment Study. JAMA Ophthalmol 2024; 142: 15-23
• 20 Upadhyay A, Beuerman RW. Biological Mechanisms of Atropine Control of Myopia. Eye Contact Lens 2020; 46: 129-135
• 21 Carr BJ, Mihara K, Ramachandran R. et al. Myopia-Inhibiting Concentrations of Muscarinic Receptor Antagonists Block Activation of Alpha2A-Adrenoceptors In Vitro . Invest Ophthalmol Vis Sci 2018; 59: 2778-2791
• 22 Barathi VA, Chaurasia SS, Poidinger M. et al. Involvement of GABA transporters in atropine-treated myopic retina as revealed by iTRAQ quantitative proteomics. J Proteome Res 2014; 13: 4647-4658
• 23 Barathi VA, Weon SR, Beuerman RW. Expression of muscarinic receptors in human and mouse sclera and their role in the regulation of scleral fibroblasts proliferation. Mol Vis 2009; 15: 1277-1293
• 24 Schwahn HN, Kaymak H, Schaeffel F. Effects of atropine on refractive development, dopamine release, and slow retinal potentials in the chick. Vis Neurosci 2000; 17: 165-176
• 25 Chiang ST, Phillips JR. Effect of Atropine Eye Drops on Choroidal Thinning Induced by Hyperopic Retinal Defocus. J Ophthalmol 2018; 2018: 8528315
• 26 Gallego P, Martínez-García C, Pérez-Merino P. et al. Scleral changes induced by atropine in chicks as an experimental model of myopia. Ophthalmic Physiol Opt 2012; 32: 478-484
• 27 Joachimsen L, Farassat N, Bleul T. et al. Side effects of topical atropine 0.05 % compared to 0.01 % for myopia control in German school children: a pilot study. Int Ophthalmol 2021; 41: 2001-2008
• 28 Cooper J, Eisenberg N, Schulman E. et al. Maximum atropine dose without clinical signs or symptoms. Optom Vis Sci 2013; 90: 1467-1472
• 29 Jones JH, Mutti DO, Jones-Jordan LA. et al. Effect of Combining 0.01 % Atropine with Soft Multifocal Contact Lenses on Myopia Progression in Children. Optom Vis Sci 2022; 99: 434-442
• 30 Tsai HR, Wang JH, Huang HK. et al. Efficacy of atropine, orthokeratology, and combined atropine with orthokeratology for childhood myopia: A systematic review and network meta-analysis. J Formos Med Assoc 2022; 121: 2490-2500
• 31 Tan Q, Ng AL, Cheng GP. et al. Combined 0.01 % atropine with orthokeratology in childhood myopia control (AOK) study: A 2-year randomized clinical trial. Cont Lens Anterior Eye 2023; 46: 101723
• 32 Nucci P, Lembo A, Schiavetti I. et al. A comparison of myopia control in European children and adolescents with defocus incorporated multiple segments (DIMS) spectacles, atropine, and combined DIMS/atropine. PLoS One 2023; 18: e0281816
• 33 Huang Z, Chen XF, He T. et al. Synergistic effects of defocus-incorporated multiple segments and atropine in slowing the progression of myopia. Sci Rep 2022; 12: 22311
• 34 Flitcroft I, Ainsworth J, Chia A. et al. IMI-Management and Investigation of High Myopia in Infants and Young Children. Invest Ophthalmol Vis Sci 2023; 64: 3
• 35 van der Sande E, Polling JR, Tideman JWL. et al. Myopia control in Mendelian forms of myopia. Ophthalmic Physiol Opt 2023; 43: 494-504
• 36 Tideman JWL, Polling JR, Vingerling JR. et al. Axial length growth and the risk of developing myopia in European children. Acta Ophthalmol 2018; 96: 301-309
• 37 Bullimore MA, Brennan NA. Myopia: An ounce of prevention is worth a pound of cure. Ophthalmic Physiol Opt 2023; 43: 116-121
• 38 Yam JC, Zhang XJ, Zhang Y. et al. Effect of Low-Concentration Atropine Eyedrops vs. Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial. JAMA 2023; 329: 472-481